信達生物(01801.HK)續漲逾10%曾再創上市新高 再有新藥獲准內地上市
信達生物(01801.HK)再有新藥獲准在內地上市,該股承過去兩連升勢,今天跑贏同業曾略升破9月中旬所創上市高位67.2元,最高見67.3元,現造67.05元,急漲逾10%,成交增至1,416萬股,涉資9.287億元。
信達生物公布,公司與禮來製藥共同開發抗體藥物達伯華(Halpryza)已正式獲得國家藥品監督管理局批准,用於在內地治療彌漫性大B細胞淋巴瘤、濾泡性淋巴瘤及慢性淋巴細胞性白血病。該藥物是繼達伯舒(信迪利單抗注射液)、達攸同(貝伐珠單抗生物類似藥)及蘇立信(阿達木單抗生物類似藥)之後,公司第四個獲得國家藥監局上市批准單克隆抗體藥物。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.